COVID‐19 Vaccine Uptake, Hesitancy, and Flare in a Large Rheumatology Practice Network

Abstract

ObjectiveThe goal of this study was to ascertain COVID‐19 vaccine uptake, reasons for hesitancy, and self‐reported flare in a large rheumatology practice‐based network.MethodsA tablet‐based survey was deployed by 108 rheumatology practices from December 2021 to December 2022. Patients were asked about COVID‐19 vaccine status and why they might not receive a vaccine or booster. We used descriptive statistics to explore the differences between vaccination status and vaccine and booster hesitancy, comparing patients with and without autoimmune and inflammatory rheumatic diseases (AIIRDs). We used multivariable logistic regression to examine the association between vaccine uptake and AIIRD status and self‐reported flare and AIIRD status. We reported adjusted odds ratios (aORs).ResultsOf the 61,158 patients, 89% reported at least one dose of vaccine; of the vaccinated, 68% reported at least one booster. Vaccinated patients were less likely to have AIIRDs (44% vs 56%). A greater proportion of patients with AIIRDs were vaccine hesitant (14% vs 10%) and booster hesitant (21% vs 16%) compared to patients without AIIRDs. Safety concerns (28%) and side effects (23%) were the main reasons for vaccine hesitancy, whereas a lack of recommendation from the physician was the primary factor for booster hesitancy (23%). Patients with AIIRD did not have increased odds of self‐reported flare or worsening disease compared to patients without with AIIRD (aOR 0.99, 95% confidence interval [CI] 0.94–1.05). Among the patients who were vaccine hesitant and booster hesitant, 12% and 39% later reported receiving a respective dose. Patients with AIIRD were 32% less likely to receive a vaccine (aOR 0.68, 95% CI 0.65–0.72) versus patients without AIIRD.ConclusionSome patients who are vaccine and booster hesitant eventually receive a vaccine dose, and future interventions tailored to patients with AIIRD may be fruitful. image